In April 2017, Alan Flake and colleagues published “An Extra-Uterine System to Physiologically Support the Extreme Premature Lamb,” hereafter “An Extra-Uterine System,” in the journal Nature Communications. “An Extra-Uterine System” reports on the development and testing of an artificial uterus system to keep alive prematurely born animals. Prematurity, or birth prior to thirty-seven weeks of gestational development, is the global leading cause of death in children under the age of five years. The artificial uterus technology, which the authors call the Biobag, is a flexible, sealable container. It’s filled with fluid and nutrients, which replicate the environment of a uterus, the organ where a fetus typically develops. Flake and colleagues showed that their Biobag technology could keep eight premature fetal lambs alive for up to four weeks. “An Extra-Uterine System” provoked discussion among scientists and the public about the possible use of the technology to improve survival rates for premature infants and the ethics of possible future uses of the technology.

James Daniel Hardy was a surgeon and researcher practicing in the United States during the twentieth century who studied organ transplantation, or the transfer of an organ from a donor to another individual. In 1963, he performed one of the first recorded lung transplants from a human lung donor. The transplant was successful for three weeks before the patient died of kidney failure. In 1964, Hardy also performed one of the first human heart transplants with a chimpanzee donor, and the transplanted heart pulsed for ninety minutes in the patient’s chest prior to death. He also collaborated on one of the first successful uterus and ovary transplants in a dog, in 1966. Hardy’s research on organ transplantation helped paved the way for improved forms of the technique, which as of 2025 saves the lives of millions of people every year.

A lymphoblastoid cell line, or LCL, is an immortalized population of cells derived from a specific type of white blood cell called a B lymphocyte that scientists around the world began using for biomedical research in the late 1960s. By immortalized, scientists mean that the cells have been altered so they can grow and divide indefinitely, or at least for an extended period of time. That trait of LCLs makes them useful as a replenishable source of cells and the DNA contained within them. Scientists obtain LCLs by first collecting a blood sample and then exposing the B lymphocytes in the blood to Epstein-Barr virus, or EBV. EBV alters the B lymphocytes in such a way that the cells begin to multiply without restraint. Researchers began making and storing LCLs from individuals around the world in the 1960s. As of 2025, LCLs form a mainstay of biomedical research, especially in human genetics and genomics.

In 1999, John Ancona Robertson, a researcher who studied bioethics and law, published “Ethics and Policy in Embryonic Stem Cell Research,” hereafter “Ethics and Policy,” in the Kennedy Institute of Ethics Journal. In the article, Robertson analyzes the ethical debates around research that uses human embryonic stem cells, or ESCs, and categorizes the different kinds of concerns within those debates. Researchers obtain human ESCs from human embryos. ESCs are pluripotent, which means they have the capability to transform into various cell types, such as skin cells or muscle cells. Robertson explains that ESCs have great medical potential, but since obtaining them requires destroying embryos, some people oppose the use of ESCs in research. After reviewing the main concerns present in debates over ESC research, he concludes that ESC research is still morally permissible. With “Ethics and Policy,” Robertson argued that ESC research should go forward and be federally funded in the US at a time when many politicians, bioethicists, and scientists opposed such research.